Variability in individual responsiveness to aspirin: Clinical implications and treatment

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 4, 2007, Pages 274-287

  Coma Canella, Isabel ^a   Velasco, Amelia ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Aspirin; Cyclooxigenase; Drug resistance; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; EXERCISE; EXTRACORPOREAL CIRCULATION; GENETIC POLYMORPHISM; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPEDANCE; LOW DRUG DOSE; PATIENT COMPLIANCE; POINT OF CARE TESTING; REVASCULARIZATION; REVIEW; SINGLE DRUG DOSE; SMOKING; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE MEMBRANE; TURBIDIMETRY; UNSPECIFIED SIDE EFFECT;

ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; RISK FACTORS; TREATMENT FAILURE;

EID: 37349026935     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907782793590     Document Type: Review

References (157)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
2. Ruggeri, Z.M. Mechanisms initiating platelet thrombus formation. Thromb. Haemost., 1997, 78, 611-616.
3. Ruggeri, Z.M. Platelets in atherotrombosis. Nat. Med., 2002, 8, 1227-1234.
4. Nieswandt, B.; Watson, S.P. Platelet-collagen interaction: is GPVI the central receptor? Blood, 2003, 102, 449-461.
5. Ibanez, B.; Vilahur, G.; Badimon, J.J. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur. Heart J., 2006, 8 (Suppl 3): G3-G9
6. Loll, P.J.; Picot, D.; Garavito, R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthese. Nat. Struct. Biol., 1995, 2, 637-643.
7. Fitzgerald, G.A.; Oates, J.A.; Hawiger, J.; Maas, R.L.; Roberts, L.J.; Lawson, J.A, Brash, A.R. Endogenous biosynthesis of prostacycline and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 1983, 71, 676-688.
8. Vane, J.R.; Bakhte, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
9. O'Neill, G.; Ford-Hutchinson, A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 1993, 330, 156-160.
10. McAdam, B.F.; Catella-Lawson, F.; Mardini I.A.; Kapoor, S.; Lawson, J.A.; FitzGerald, G. Systemic biosynthesis of prostacyclin by cyclooxygenase-2. The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad, Sci. U.S.A., 1999, 96, 272-277.
11. Schonbeck, U.; Sukhova, G.K.; Graber, P.; Coulter, S.; Libby, P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol., 1999, 155, 1281-1291.
12. Weber, A.A.; Zimmermann, K.; Meyer-Kirchrath, J. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet, 1999, 353, 900.
13. Zimmermann, N.; Wenk, A.; Kim, U.; Kienzle, P.; Weber, A.A.; Gams, E.; Schror, K.; Hohlfeld, T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery by pass surgery. Circulation, 2003, 108, 542-547.
14. Rocca, B.; Secchiero, P.; Ciabattoni, G.; Ranelletti, F.O.; Catani, L.; Guidotti, L.; Melloni, E.; Maggiano, N.; Zauli, G.; Patrono, C. Cyclooxygenase-2 expression is induced during human megakaryopoesis and characterizes newly formed platelets. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 7634-7639.
15. Antman, E.M.; DeMets, D.; Loscalzo, J. Cyclooxygenase inhibition and cardiovascular risk. Circulation, 2005, 112, 759-770.
16. Ellis, E.F.; Wright, K.F.; Jones, P.S.; Richardson, D.W.; Ellis, C.K. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans and rabbits. J. Cardiovasc. Pharmacol., 1980, 4, 387-397.
17. Awtry, E.H.; Loscalzo, J. Aspirin. Circulation, 2000, 101, 1206-1218.
18. McAdam, B.F.; Catella-Lawson, F.; Mardini, I.A.; Kapoor, S.; Lawson, J.A.; FitzGerald, G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 272-277.
19. 2 but not systemic prostacyclin by controlled release aspirin. N. Engl. J. Med., 1991, 325, 1137-1141.
20. Undas, A.; Brummel-Ziedins, K.E, Mann, K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood, 2007, 109, 2285-2292.
21. Altman, R.; Luciardi, H.L.; Muntaner, J.; Herrera, R.N. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J., 2004, 2, 1.
22. Steer, K.A.; Wallace, T.M.; Bolton, C.H.; Hartog, M. Aspirin protects low density lipoprotein from oxidative modification. Heart, 1997, 77, 333-337.
23. Husain, S.; Andrews, N.P.; Mulcahy, D.; Panza, J.A, Quyyumi, A.A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation, 1998, 97, 716-720.
24. Nannizzi-Alaimo, L.; Alves, V.L.; Phillips, D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation, 2003, 107, 1123-1128.
25. Williams, F.M. Clinical significance of esterases in man. Clin. Pharmacokinet., 1985, 10, 392-403.
26. Cipollone, F.; Patrignani, P.; Greco, A.; Panara, M.R.; Padovano, R.; Cuccurullo, F.; Patrono, C.; Rebuzzi, A.G.; Liuzzo, G.; Quaranta, G.; Maseri, A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation, 1997, 96, 1109-1116.
27. Patrono, C.; Coller, B.; FitzGerald, G.A.; Hirsh, J.; Roth, G. Platelet-acive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126 (Suppl 3), 234S-264S.
28. Patrignani, P.; Filabozzi, P.; Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest., 1982, 69, 1366-1372.
29. Bornstein, N.M.; Karepov, V.G.; Aronovich, B.D.; Gorbulev, A. Y.; Treves, T.A.; Korczyn, A.D. Failure of aspirin treatment after stroke. Stroke, 1994, 25, 275-277.
30. Hennekens, C.H.; Schror, K.; Weisman, S.; FitzGerald, G.A. Terms and conditions: semantic complexity and aspirin resistance. Circulation, 2004, 110, 1706-1708.
31. Eikelboom, J.W.; Hirsh, J.; Weitz, J.L; Johnston, M.; Yi, Q.; Yusuf, S. Aspirin-resistant thromboxime biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002, 105, 1650-1655.
32. Patrono, C. Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemost., 2003, 1, 1710-1713.
33. Patrono, C.; Rocca, B. Drug Insight: aspirin resistance-fact or fashion? Nature Clin. Practice Cardiov. Med., 2007, 4, 42-50.
34. Gum, P.A.; Kottke-Marchant, K.; Poggio, E.D.; Gurm, H.; Welsh, P.A.; Brooks, L.; Sapp, S.K.; Topol, E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol., 2001, 88, 230-235.
35. Mueller, M.R.; Salat, A.; Stangel, P.; Murabito, M.; Pulaki, S.; Boehm, D.; Koppensteiner, R.; Ergun, E.; Mittlboeck, M.; Schreiner, W.; Losert, U.; Wolner, E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb. Haemost., 1997, 78, 1003-1007.
36. Coma-Canella, I.; Velasco, A.; Castano, S. Prevalence of aspirin resistance measured by PFA-100. Int. J. Cardiol., 2005, 101, 71-76.
37. Martin, C.P.; Talbert, R.L. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy, 2005, 25, 942-953.
38. Cipollone, F.; Ciabattoni, G.; Patrignani, P.; Pasquale, M.; Di Gregorio, D.; Bucciarelli, T.; Davi, G.; Cuccurullo, F.; Patrono, C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, 2000, 102, 1007-1013.
39. Marcus, A.J. In Disorders of Hemostasis; Ratnoff, O.D.; Forbes, C.D.; Eds.; WB Saunders: Philadelphia, 1996; pp. 79-137.
40. Coller, B.S In The Heart and Cardiovascular System; Frozzard, H.A, Haber, E, Jennings, R.B, Katz, A.M, Morgan, H.E, Eds. Raven Press: New York, 1992, pp. 219-273.
41. Santos, M.T.; Valles, J.; Marcus, A.J.; Safier, L.B.; Broekman, M.J.; Islam, N.; Ullman, H.L.; Eiroa, A.M.; Aznar, J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J. Clin. Invest., 1991, 87, 571-580.
42. Valles, J.; Santos, M.T.; Aznar, J.; Marcus, A.J.; Martinez-Sales, V.; Portoles, M.; Broekman, M.J.; Safier, L.B. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood, 1991, 78, 154-162.
43. MacDonald, T.M.; Wei, L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003, 361, 573-574.
44. Kurth, T.; Glynn, R.J.; Walker, A.M.; Chan, K.A.; Buring, J.E.; Hennekens, C.H.; Gaziano, J.M. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation, 2003, 108, 1191-1195.
45. Michelson, A.D.; Cattaneo, M.; Eikelboom, J.W.; Gurbel, P.; Kottke-Marchant, K.; Kunicki, T.J.; Pulcinelli, F.M.; Cerletti, C.; Rao, A.K. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost., 2005, 3, 1309-1311.
46. Kratzer, M.A.; Born, G.V. Simulation of primary haemostasis in vitro. Haemostasis, 1985, 15, 357-362.
47. Cardigan, R.; Turner, C.; Harrison, P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sanguinis, 2005, 88, 153-163.
48. Favaloro, E.J.; Facey, D.; Henniker, A. Use of a novel platele function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am. J. Hematol., 1999, 62, 165-174.
49. Heilmann, E.J.; Kundu, S.K.; Sio, R.; Garcia, C.; Gomez, R.; Christie, D.J. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system Thromb Res., 1997, 87, 159-164.
50. Marshall, P.W.; Williams, A.J.; Dixon, R.M.; Growcott, J.W.; Warburton, S.; Armstrong, J.; Moores, J. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br. J. Clin. Pharmacol., 1997, 44, 151-155.
51. Hankey, G.J.; Eikelboom, J.W. Aspirin resistance. Lancet, 2006 367, 606-617.
52. Hart, R.G.; Leonard, A.D.; Talbert, R.L.; Pearce, L.A.; Cornell, E.; Bovill, E.; Feinberg, W.M. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy, 2003, 23, 579-584.
53. Dippel, D.W.; Van Kooten, F.; Leebeek, F.W.; van Vliet, H.H.; Mehicevic, A.; Li, S.S.; Koudstaal, P.J. What is the lowest dose of aspirin for maximum suppression of in-vivo thromboxane production after a transient ischaemic attack or ischaemic stroke? Cerebrovasc. Dis., 2004, 17, 296-302.
54. Lakkis, N.M.; George, S.; Thomas, E.; Ali, M.; Guyer, K.; Carville, D. Use of ICHOR-Platelet Works to Assess Platelet Function in Patients Treated With GPIIb/IIIa Inhibitors. Cathet. Cardiovasc. Intervent., 2001, 53, 346-351.
55. Harrison, P.; Segal, H.; Blasbery, K.; Furtado, C.; Silver, L.; Rothwell, P.M. Screening for Aspirin Responsiveness After Transient Ischemic Attack and Stroke. Comparison of 2 Point-of-Care Platelet Function Tests With Optical Aggregometry. Stroke, 2005, 36, 1001-1005.
56. Gum, P.A.; Kottke-Marchant, K.; Welsh, P.A.; White, J.; Topol, E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol., 2003, 41, 961-965.
57. Campo, G.; Valgimigli, M.; Gemmati, D.; Percoco, G.; Tognazzo, S.; Cicchitelli, G.; Catozzi, L.; Malagutti, P.; Anselmi, M.; Vassanelli, C.; Scapoli, G.; Ferrari, R. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J. Am. Coll. Cardiol., 2006, 48, 2178-2185.
58. Chakroun, T.; Gerotziafas, G.; Robert, F.; Lecrubier, C.; Samama, M.M.; Hatmi, M.; Elalamy, I. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br. J. Haematol., 2004, 124, 80-85.
59. Alberts, M.J.; Bergman, D.L.; Molner, E, Jovanovic, B.D, Ushiwata, I, Teruya, J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke, 2004, 35, 175-178.
60. Macchi, L.; Christiaens, L.; Brabant, S.; Sorel, N.; Allal, J.; Mauco, G.; Brizard, A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res., 2002, 107, 45-49.
61. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Ramirez, C.; Sabate, M.; Jimenez-Quevedo, P.; Hernandez, R.; Moreno, R.; Escaned, J.; Alfonso, F.; Banuelos, C.; Costa, M.A.; Bass, T.A.; Macaya, C. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol., 2006, 97, 38-43.
62. Lev, E.I.; Patel, R.T.; Maresh, K.J.; Guthikonda, S.; Granada, J.; DeLao, T.; Bray, P.F.; Kleiman, N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol., 2006, 47, 27-33.
63. Poulsen, T.S.; Kristensen, S.R.; Korsholm, L.; Haghfelt, T.; Jorgensen, B.; Licht, P.B.; Mickley, H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb. Res., 2007, 120, 477-94.
64. Helgason, C.M.; Bolin, K.M.; Hoff, J.A.; Winkler, S.R.; Mangat, A.; Tortorice, K.L.; Brace, L.D. Development of aspirin resistance in persons with previous ischemic stroke. Stroke, 1994, 25, 2331-2336.
65. Pulcinelli, F.M.; Pignatelli, P.; Celestial, A.; Riondino, S.; Gazzaniga, P.P.; Violi, F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. Cardiol., 2004, 43, 979-984.
66. Antman, E.M.; Anbe, D.T.; Armstrong, P.W.; Bates, E.R.; Green, L.A.; Hand, M.; Hochman, J.S.; Krumholz, H.M.; Kushner, F.G.; Lamas, G.A.; Mullany, C.J.; Ornato, J.P.; Pearle, D.L.; Sloan, M.A.; Smith, S.C. Jr.; Alpert, J.S.; Anderson, J.L.; Faxon, D.P.; Fuster, V.; Gibbons, R.J.; Gregoratos, G.; Halperin, J.L.; Hiratzka, L.F.; Hunt, S.A.; Jacobs, A.K.; Ornato, J.P. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J. Am. Coll. Cardiol., 2004, 44(3), E1-E211.
67. Grotemeyer, K.H.; Scharafinski, H.W.; Husstedt, I.W. Two year follow-up of aspirin responders and aspirin non-responders. A pilot study including 180 post-stroke patients. Thromb. Res., 1993, 71, 397-403.
68. Gurbel, P.A., Tantry, U.S. Aspirin and clopidogrel resistance: Consideration and management. J. Interv. Cardiol., 2006, 19, 439-448.
69. ten Berg, J.M.; Gerritsen, W.B.; Haas, F.J.; Kelder, J.C.; Verheugt, F.W.; Plokker, H.W. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb. Res., 2002, 105, 385-390.
70. Lee, P.Y.; Chen, W.H, Ng, W.; Cheng, X.; Kwok, J.Y.; Tse, H.F.; Lau, C.P. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med., 2005, 118, 723-727.
71. Roller, R.E.; Dorr, A.; Ulrich, S.; Pilger, E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul. Fibrinolysis, 2002; 13, 277-281.
72. Mirkhel, A.; Peyster, E.; Sundeen, J.; Greene, L.; Michelson, A.D.; Hasan, A.; Domanski, M. Frequency of aspirin resistance in a community hospital. Am. J. Cardiol., 2006, 98, 577-579.
73. Friend, M.; Vucenik, I.; Miller, M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. B. M. J., 2003, 326, 82-83.
74. De Is Cruz, J.P.; Arrebola, M.M.; Villalobos, M.A.; Pinacho, A.; Guerrero, A.; González-Correa, J.A.; Sánchez de la Cuesta, F. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur. J. Pharmacol., 2004, 484, 19-27.
75. Davis, J.W.; Hartman, C.R.; Lewis, H.D.; Shelton, L.; Eigenberg, D.A.; Hassanein, K.M.; Hignite, C.E.; Ruttinger, H.A. Cigarette smoking-induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J. Lab. Clin. Med., 1985, 105, 479-483.
76. Csiszar, A.; Stef, G.; Pacher, P.; Ungvari, Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66, 557-558.
77. Szczeklik, A.; Musial, J.; Undas, A.; Gajewski, P.; Gora, P.; Swadzba, J.; Jankowski, M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J. Am. Coll Cardiol., 1999, 33, 1286-1293.
78. Watala, C.; Ulicna, O.; Golanski, J.; Nocun, M.; Waczulikova, I.; Markuszewski, L.; Drewoski, J. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul. Fibrinolysis, 2006, 17, 113-124.
79. Vaidyula, V.R.; Boden, G.; Rao, A.K. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets, 2006, 17, 577-585.
80. Watala, C.; Pluta, J.; Golanski, J.; Rozalski, M.; Czyz, M.; Trojanowski, Z.; Drzewoski, J. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med., 2005, 83, 148-158.
81. Hobikoglu, G.F.; Norgaz, T.; Aksu, H.; Ozer, O.; Erturk, M.; Destegul, E.; Akyuz, U.; Unal Dai, S.; Narin. A. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can. J. Cardiol., 2007, 23, 201-206
82. Antman, E.M.; Cohen, M.; Bernink, P.J.; McCabe, C.H.; Horacek, T.; Papuchis, G.; Mautner, B.; Corbalan, R.; Radley, D.; Braunwald, E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA, 2000, 284, 835-942.
83. Wells, B.; Gentry, M.; Ruiz-Arango, A.; Dias, J.; Landolfo, C.K. Relation between body mass index and clinical outcome in acute myocardial infarction. Am. J. Cardiol., 2006, 98, 474-477.
84. Chen, W.H.; Lee, P.Y.; Ng, W.; Tse, H.F.; Lau, C.P. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pre-treatement. J. Am. Coll. Cardiol., 2004, 43, 1122-1126.
85. Wenaweser, P.; Dorffler-Melly, J.; Imboden, K.; Windecker, S.; Togni, M.; Meier, B.; Haeberli, A.; Hess, O.M. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J. Am. Coll. Cardiol., 2005, 45, 1748-1752.
86. Velasco, A.; Cordero, A.; Fernandez-Jame, E.; Coma-Canella, I. Infarto agudo de miocardio y trombosis subaguda intra-stent en un paciente con resistencia. a la aspirina. Med. Clin., 2005, 125, 79.
87. Grotemeyer, K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res., 1991, 63, 587-593.
88. Libby, P. Molecular bases of the acute coronary syndromes. Circulation, 1995, 91, 2844-2850.
89. Belton, O.; Byrne, D.; Kearney, D.; Leahy, A.; Fitzgerald, D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 2000, 102, 840-845.
90. Serebruany, V.L.; Malinin, A.I.; Jerome, S.D.; Lowry, D.R.; Morgan, A.W.; Sane, D.C.; Tanguay, J.F.; Steinhubl, S.R.; O'connor, C.M. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am. Heart. J., 2003, 146, 713-720.
91. Schafer, A.; Eigenthaler, M.; Bauersachs, J. Platelet activation in heart failure. Clin. Lab., 2004, 50, 559-566.
92. Lip, G.Y.; Gibbs, C.R. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J. Am. Coll. Cardiol., 1999, 33, 1424-1426.
93. Rostrup, M.; Westheim, A.; Refsum, H.E.; Hotme, L; Eide, I. Arterial and venous plasma catecholamines during submaximal steady-state exercise. Clin. Physiol., 1998, 118, 109-115.
94. Wang, J.S.; Jen, C.J.; Kung, H.C.; Lin, L.J.; Hsiue, T.R.; Chen H.I. Different effects of strenuous exercise and moderate exercise on platelet function in men. Circulation, 1994, 90, 2877-2885.
95. Larsson, P.T.; Wallen, N.H.; Hejmdahl, P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation, 1994, 89, 1951-1957.
96. Pamukcu, B.; Ofiaz, H.; Acar, R.D.; Umman, S.; Koylan, N.; Umman, B.; Nisanci, Y. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J. Thromb. Thrombolysis, 2005, 20, 17-22.
97. Christiaens, L.; Macchi, L.; Herpin, D.; Coisne, D.; Duplantier, C.; Allal, J.; Mauco, G.; Brizard, A. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb. Res., 2003, 108, 115-119.
98. Guhnez, O.; Yildirir, A.; Bal, U.; Konas, N.D.; Aydinalp, A.; Demir, O.; Atar, I; Ertan, C.; Ozin, B.; Muderrisoglu, H. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. Blood Coagul. Fibrinolysis, 2007, 18, 9-13.
99. Kuliczkowski, W.; Kobusiak-Prokopowicz, M.; Prajs, I.; Karolko, B.; Mazurek, W. Aspirin failure course during exercise and its connection with soluble CD40L. Thromb. Res., 2007, 119, 679-686.
100. Hurlen, M.; Seljeflot L; Arnesen, H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb. Res., 2000, 99, 487-494.
101. Toller, G.H.; Brezinski, D.; Schafer, A.I.; Czeisler, C.A.; Rutherford, J.D.; Willich, S.N.; Gleason, R.E.; Williams, G.H.; Muller, J.E. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N. Engl. J. Med, 1987, 316, 1514-1518.
102. Fujimura, A, Ohashi, K, Ebihara, A. Daily variations in platelet aggregation and adhesion in healthy subjects. Life Sci., 1992, 50, 1043-1047.
103. Jafri, S.M.; VanRollins, M.; Ozawa, T.; Mammen, E.F.; Goldberg, A.D.; Goldstein, S. Circadian variation in platelet function in healthy volunteers. Am. J. Cardiol., 1992, 69, 951-954.
104. Ridker, P.M.; Manson, J.E.; Buring, J.E.; Muller, J.E.; Hennekens, C.H. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation, 1990, 82, 897-902.
105. Velasco, A.; Coma-Canella, I; Moreno, J. Aspirin resistance has a circadian rhythm. J. Coronary Artery Dis., 2005, 6, 67-68.
106. Dalby, M.C.; Davidson, S.J.; Burman, J.F.; Davies, S.W. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets, 2000, 11, 320-324.
107. Anand, B.S.; Sanduja, S.K.; Lichtenberger, L.M. Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers. Gastroenterology, 1999, 116, A371.
108. Iñarrea, P.; Esteva, F.; Comudella, R.; Lanas, A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand. J. Gastroenterol., 2000, 35, 242-246.
109. Hergovich, N.; Aigner, M.; Eichler, H.G.; Entlicher, J.; Drucker, C.; Jilma, B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther., 2000; 68, 435-442.
110. Cahill, R.A.; McGreal, G.T.; Crowe, B.H.; Ryan, D.A.; Manning, B.J.; Cahill, M.R.; Redmond, H.P. Duration of increased bleeding tendency after cessation of aspirin therapy. J. Am. Coll. Surg., 2005, 200, 564-573.
111. Goldenberg, N.A.; Jacobson, L.; Manco-Johnson, MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann. Intern. Med., 2005, 142, 506-509.
112. Kimmel, S.E.; Berlin, JA.; Reilly, M.; Jaskowiak, J.; Kishel, L.; Chittams, J.; Strom, B.L. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol., 2004, 43, 985-990.
113. Catella-Lawson, F.; Reilly, M.P.; Kapoor, S.C.; Cucchiara, A.J.; DeMareo, S.; Tournier, B.; Vyas, S.N.; FitzGerald, G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med., 2001, 345, 1809-1817.
114. Capone, M.L.; Sciulli, M.G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di Gregorio, P.; Merciaro, G.; Patrignani, P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol., 2005, 45; 1295-1301.
115. Hippisley-Cox, J.; Coupland, C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med. J., 2005, 330, 1366.
116. Zarraga, I.G.; Schwarz, E.R. Coxibs and heart disease; what we have learned and what else we need to know. J. Am. Coll. Cardiol., 2007, 49, 144.
117. Bhatt, D.L. NSAIDS and the risk of myocardial infarction: do they help or harm? Eur Heart. J., 2006, 27, 1635-1636.
118. Concomitant Use of Ibuprofen and Aspirin: Potential for Attenuation of the Anti-Platelet Effect of Aspirin. Food and Drug Administration Science Paper. September 8, 2006 (http://www.fda.gov/cder/ drug/infopage/ibuprofen/science_paper.htm).
119. Halushka, M.K.; Walker, L.P.; Halushka, P. V. Genetic variation in cyclooxygenase-1: effects on response to aspirin. Clin. Pharmacol. Ther., 2003, 73, 122-130.
120. Cambria-Kiely, JA.; Gandhi, P.J. Aspirin resistance and genetic polymorphisms. J. Thromb. Thrombolysis, 2002, 14, 51-58.
121. Maree, A.O.; Curtin, R.J.; Chubb, A.; Dolan, C.; Cox, D.; O'Brien, J.; Crean, P.; Shields, D.C.; Fitzgerald, D.J. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J. Thromb. Haemost., 2005, 3, 2340-2345.
122. Cipollone, F.; Toniato, E.; Martinotti, S.; Fazia, M.; Iezzi, A.; Cuccurullo, C.; Pini, B.; Ursi, S.; Vitullo, G.; Averna, M.; Arcs, M.; Montali, A.; Campagna, F.; Ucchino, F.; Spigonardo, F.; Taddei, S.; Virdis, A.; Ciabattoni, G.; Notarbartolo, A.; Cuccurullo, F.; Mezzeti, A. Identification of New Elements of plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction or stroke. JAMA, 2004, 29, 2221-2228.
123. Andrioli, G.; Minuz, P.; Solero, P.; Pincelli, S.; Ortolani, R.; Lussignoli, S.; Bellavite, P. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with P1(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br. J. Haematol., 2000, 110, 911-918.
124. Pontiggia, L.; Lassila, R.; Pederiva, S.; Schmid, H.R.; Burger, M.; Beer, J.H. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GP Ia and GP IIIa. Arterioscler Thromb. Vasc. Biol., 2002, 22, 2093-2098.
125. Quinn, M.J.; Topol, E.J. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics, 2001, 2, 341-352.
126. Jefferson, B.K.; Foster, J.H.; McCarthy, J.J.; Ginsburg, G.; Parker, A.; Kottke-Marchant, K.; Topol, E.J. Aspirin resistance and a single gene. Am. J. Cardiol., 2005, 95, 805-808.
127. Chakroun, T.; Gerotziafas, G.; Robert F.; Lecrubier, C.; Samama, M.M.; Hatmi, M.; Elalamy, I. In vitro aspirin resistance detected by PFA-100™ closure time: pivotal role of plasma von Willebrand factor. BMH, 2003, 124, 80-85.
128. Malinin, A.; Spergling, M.; Muhlestein, B.; Steinhubl, S.; Serebruany, V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul. Fibrinolysis, 2004, 15(4), 295-301.
129. Bonclera, M.; Luzaka, B.; Rozalskia, M.; Golanskia, J.; Rychlikb, B.; Watala, C. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb. Res., 2007, 119(2), 209-216.
130. Kundu, S.K.; Heilmann, E.J.; Sio, R.; Garcia, C.; Ostgaard, RA. Characterization of an in vitro platelet function analyzer - PFA-100. Clin. Appl. Thromb. Hemost., 1996, 2, 241-249.
131. Harrison, P.; Robinson, M.S.; Mackie, I.J.; Joseph, J.; McDonald, S.J.; Liesner, R.; Savidge, G.F.; Pasi, J.; Machin, S.J. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul. Fibrinolysis, 1999; 10, 25-31.
132. Harrison, P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br. J. Haematol., 2005, 130, 3-10.
133. Fressinaud, E.; Veyradier, A.; Truchaud, F.; Martin, I.; Boyer-Neumann, C.; Trossaert, M.; Meyer, D. Screening for von Wille-brand disease with a new analyzer using high shear stress: a study of 60 cases. Blood, 1998, 91, 1325-1331.
134. DiPaola, J.; Federici, A.B.; Mannucci, P.M.; Canciani, M.T.; Kritzik, M.; Kunicki, T.J.; Nugent, D. Low platelet alpha2beta1 levels in type 1 von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood, 1999, 93, 3578-3582.
135. Lippi, G.; Franchini, M.; Brocco, G.; Manzato, F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb. Haemost., 2001, 85, 369-370.
136. Pearson, D.A.; Paglieroni, T.G.; Rein, D.; Wun, T.; Schramm, D.D.; Wang, J.F.; Holt, R.R.; Gosselin, R.; Schmitz, H.H.; Keen, C.L. The effects of flavonoid-rich cocoa and aspirin on ex vivo platelet function. Thromb. Res., 2002, 106, 191-197.
137. Grundmann, K.; Jaschonek, K.; Kleine, B.; Dichgans, J.; Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol., 2003, 250, 63-66.
138. McCabe, D.J.; Harrison, P.; Mackie, I.J.; Sidhu, P.S.; Lawrie, A.S.; Purdy, G.; Machin, S.J.; Brown, M.M. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets, 2005, 5, 269-280.
139. Andersen, K.; Hurlen, M.; Amesen, H.; Seljeflot, I. Aspirin nonresponsivenessas measured by PFA-100 in patients with coronary artery disease. Thromb. Res., 2002, 108, 37-42.
140. Pamukcu, B.; Oflaz, H.; Oncul, A.; Umman, B.; Mercanoglu, F.; Ozcan, M.; Meric, M.; Nisancy, Y. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J. Thromb. Thrombolysis, 2006, 22, 103-110.
141. Fuchs, I.; Frossard, M.; Spiel, A.; Riedmuller, E.; Laggner, A.N.; Jilma, B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J. Thromb. Haemost., 2006, 4, 2547-2552.
142. Marcucci, R.; Paniccia, R.; Antonucci, E.; Gori, A.M.; Fedi, S.; Giglioli, C.; Valente, S.; Prisco, D.; Abbate, R.; Gensini, G.F. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am. J. Cardiol., 2006, 98, 1156-1159.
143. Lee, P.Y.; Chen, W.H.; Ng, W.; Cheng, X.; Kwok, J.Y.Y.; Tse, H.F.; Lau, C.P. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med., 2005, 118, 723-727.
144. Valles, J.; Santos, M.T.; Aznar, J.; Osa, A.; Lago, A.; Cosin, J.; Sanchez, E.; Broekman, M.J.; Marcus, A.J. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation, 1998, 97, 350-355.
145. Ridker, P.M.; Cook, N.R.; Lee, I.M.; Gordon, D.; Gaziano, J.M.; Manson, J.E.; Hennekens, C.H, Buring, J.E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005; 352, 1293-1304.
146. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol., 2006, 47, 216-235.
147. Cannon, C.P.; McLean, D.S. Critical pathways using platelet testing to potentially optimize the use of oral antiplatetet therapy. Am. J. Cardiol., 2006, 98 (Suppl), 33N-38N.
148. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet, 1996, 348, 1329-1339.
149. Ringleb, P.A.; Bhatt, D.L.; Hirsch, A.T.; Topol, E.J.; Hacke, W. Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 2004, 35, 528-532.
150. Matetzky, S.; Shenkman, B.; Guetta, V.; Schechter, M.; Bienart, R.; Goldenberg, I.; Novikov, I.; Pres, H.; Savion, N.; Varon, D.; Hod, H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004, 109, 3171-3175.
151. Eikelboom, J.W.; Hankey, G.J.; Thom, J.; Claxton, A.; Yi, Q.; Gilmore, G.; Staton, J.; Barden, A.; Norman, P.E. Enhanced anti-platelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J. Thromb. Haemost., 2005, 3, 2649-2655.
152. Mehta, S.R.; Yusuf, S.; Peters, R.J.; Bertrand, M.E.; Lewis, B.S.; Natarajan, M.K.; Malmberg, K.; Rupprecht, H.; Zhao, F.; Chrolavicius, S.; Copland, I.; Fox, K.A. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 2001, 358, 527-533.
153. Steinhubl, S. R.; Berger, P.B.; Mann, J.T. 3rd, Fry, E.T.; DeLago, A.; Wilmer, C.; Topol, E.J. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. JAMA, 2002, 288, 2411-2420.
154. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 366, 1607-1621.
155. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Invertigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345, 494-502.
156. Muller, C.; Buttner, H.J.; Petersen, J.; Roskamm, H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation, 2000, 101, 590-593.
157. Taniuchi, M.; Kurz, H.I.; Lasala, J.M. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation, 2001, 104, 539-543.